#specialty medicine#late-stage pipeline programs#clinical a

BioMarin promotes Jeff Ajer to the post of Senior VP, Chief Commercial Officer

BioMarin Pharmaceuticals Inc Thursday said it has announced that Jeff Ajer, the present Vice President, Commercial Operations; the Americas will be pro...

Admin
|Sep 6|magazine4 min read

BioMarin Pharmaceuticals Inc Thursday said it has announced that Jeff Ajer, the present Vice President, Commercial Operations; the Americas will be promoted to the post of Senior Vice President, Chief Commercial Officer.  

Mr. Ajer has over more than 20 years of experience in building industry-leading  commercial companies within rare disease and specialty medicine.

Mr. Ajer will also be leading the company’s global marketing and sales companies and report directly to CEO of BioMarin Jean –Jacques Bienaimé.  His recent role involved P&L responsibility for commercial operations throughout the Americas, including the markets critical for company growth such as Brazil and the U.S. He also led the product marketing, reimbursement and sales operations for BioMarin. 

He has also played a leadership role in establishing  BioMarin’s successful  commercial infrastructure and global footprint, shaped the launches and growth strategies for Naglazyme and Kuvan.

Jeff also led the commercial planning for late-stage pipeline programs including GALNS.  He joined the company in 2005 as a Vice President of Sales and Marketing Operations.  Before being part of BioMarin, Mr. Ajer  also served as Vice President, Global Transplant Operations at Genzyme Corporation.   

The Executive Vice President, Chief Business Officer, Stephen Aselage will be leaving the company to pursue opportunities from October 15.  He will also get a severance package based on the terms of his employment agreement.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved drugs and multiple clinical and pre-clinical product candidates.